The US Food and Drug Administration (FDA) has approved the novel calcimimetic etelcalcetide (Parsabiv, Amgen) for the treatment of secondary hyperparathyroidism in adults on hemodialysis.

Please provide your email address to receive an email when new articles are posted on . A lower parathyroid hormone target treatment method was linked with reduced adjusted hazard of death. The ...

Please provide your email address to receive an email when new articles are posted on . In the study, 67% of patients receiving upacicalcet achieved target parathyroid hormone concentrations. Overall, ...

The appraisal committee reviewed the data available on the clinical and cost effectiveness of etelcalcetide, having considered evidence on the nature of secondary hyperparathyroidism and the value ...

This section presents medications that are known to potentially lead to 'Hyperparathyroidism secondary' as a side effect. It's important to note that mild side effects are quite common with ...

The European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) had recommended approval of etelcalcetide (Parsabiv, Amgen Europe BV) for the treatment of secondary ...

Gastritis Predisposes Diabetes Patients to Metformin’s GI Effects If validated, new study findings may be used to develop a disease-specific patient-reported outcome measure that will inform SHPT ...

Loop diuretics increase the risk of secondary hyperparathyroidism in CKD patients, but concurrent use of thiazide diuretics attenuate that risk. Subjects on loop diuretics had a 2.4 times increased ...

SECONDARY hyperparathyroidism associated with chronic renal disease may simulate primary hyper-parathyroidism with secondary renal impairment in virtually every particular. An exception is the brown ...

Hyperparathyroidism happens when the parathyroid glands make too much parathyroid hormone. This can affect your calcium levels and cause other health problems. You may have hyperparathyroidism if your ...